| 1 |
NCT02412709 |
Recruiting |
Long QT Syndrome Screening in Newborns |
|
- Device: QTScreen ECG Recorder
|
Interventional |
Phase 2 |
- QT Medical, Inc.
- Los Angeles Biomedical Research Institute
- University of California, Irvine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Determine LQTS risk via QTc Measurement and family/personal history
- Determine if parents are able to use QTScreen on babies at home
- Follow-up for false negatives and survey end-user experience
- Estimate the LQTS prevalence in California
|
4000 |
All |
up to 4 Weeks (Child) |
NCT02412709 |
30147-01 |
|
June 2015 |
December 2016 |
March 2017 |
April 9, 2015 |
September 28, 2016 |
|
- St. Francis Medical Center
Lynwood, California, United States - Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California, United States - Providence Little Company of Mary Medical Center-Torrance
Torrance, California, United States
|
| 2 |
NCT02876380 |
Recruiting |
Prospective Identification of Long QT Syndrome in Fetal Life |
|
|
Observational |
|
- University of Colorado, Denver
- Children's Hospital Colorado
- University of Pavia
- (and 14 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Effectiveness of an Fetal Heart Rate/Gestational Age, FHR/GA, Algorithm
- Differences in the Receiver Operating Characteristic (ROC) of FHR/GA vs gold standard of genetic testing
|
600 |
All |
18 Years to 45 Years (Adult) |
NCT02876380 |
13-3129 |
Fetal LQTS |
November 2014 |
December 2020 |
December 2020 |
August 23, 2016 |
September 5, 2017 |
|
- Children's Hospital Colorado
Aurora, Colorado, United States
|
| 3 |
NCT02425189 |
Recruiting |
The Canadian National Long QT Syndrome Registry |
|
|
Observational |
|
- Andrew Krahn
- University of British Columbia
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Natural Course of Long QT
|
600 |
All |
Child, Adult, Senior |
NCT02425189 |
H14-02344 |
LQTSREG |
November 2014 |
December 2020 |
December 2021 |
April 23, 2015 |
May 17, 2016 |
|
- University of British Columbia
Vancouver, British Columbia, Canada
|
| 4 |
NCT02680080 |
Active, not recruiting |
Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome |
|
- Drug: Moxifloxacin
- Dietary Supplement: Grapefruit group
|
Interventional |
Not Applicable |
- Tel-Aviv Sourasky Medical Center
- Tel Aviv Medical Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
|
35 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02680080 |
TASMC-15-EC-15-0728-TLV-CTIL |
|
December 1, 2016 |
January 31, 2019 |
February 28, 2020 |
February 11, 2016 |
February 15, 2018 |
|
- Sourasky medical center (Ichilov)
Tel-Aviv, Israel
|
| 5 |
NCT02300558 |
Terminated
Has Results |
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3 |
|
- Drug: Eleclazine
- Drug: Eleclazine placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Change From Baseline in Mean Daytime QT Interval in Lead V5 Corrected for Heart Rate Using the Fridericia Formula (QTcF) Interval to Week 24 (Based on Standard 12-lead ECG Data)
- Change From Baseline in Mean Daytime QTcF Interval (AUC0-6/6) to Week 12 (Lead V5; Standard 12-lead ECG)
- Change From Baseline in Mean Daily (Daytime and Nocturnal) QTcF Interval to Week 24 (Lead V5; Holter)
- Change From Baseline in Mean Nocturnal QTcF Interval to Week 24 (Lead V5; Holter)
|
41 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02300558 |
GS-US-372-1234
2014-000042-30 |
|
December 17, 2014 |
December 12, 2016 |
February 15, 2017 |
November 25, 2014 |
January 12, 2018 |
January 12, 2018 |
- Mayo Clinic Rochester
Rochester, Minnesota, United States - NYU Langone Medical Center
New York, New York, United States - University of Rochester Medical Center
Rochester, New York, United States - (and 9 more...)
|
| 6 |
NCT02581241 |
Completed |
Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome |
|
|
Interventional |
Not Applicable |
- Tel-Aviv Sourasky Medical Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- ECG measurements of QT before and during stand up test
|
5 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02581241 |
TASMC-15-EC-0379-15-CTIL |
|
January 1, 2016 |
August 17, 2017 |
August 23, 2017 |
October 20, 2015 |
February 15, 2018 |
|
- Sourasky medical center (Ichilov)
Tel-Aviv, Israel
|
| 7 |
NCT01705925 |
Active, not recruiting |
Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome |
|
|
Observational |
|
- Mednax Center for Research, Education, Quality and Safety
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Adverse Cardiac Events on patients with genotype positive LQT1 who have a normal EKG and absence of symptoms, but a molecular confirmation of LQT1.
- Adverse Cardiac Events on patients with both phenotype and genotype positive.
|
500 |
All |
up to 20 Years (Child, Adult) |
NCT01705925 |
PDX-002-11 |
|
March 2012 |
December 2019 |
December 2019 |
October 12, 2012 |
February 1, 2018 |
|
- Arizona Pediatric Cardiology Consultants
Phoenix, Arizona, United States - Children's Cardiology Associates
Austin, Texas, United States
|
| 8 |
NCT00488254 |
Completed |
The Long QT Syndrome in Pregnancy |
|
|
Observational |
|
- University of British Columbia
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
|
12 |
Female |
Child, Adult, Senior |
NCT00488254 |
H06-03385 |
|
June 2007 |
|
April 2008 |
June 20, 2007 |
April 14, 2011 |
|
- BC Women's Hospital
Vancouver, British Columbia, Canada
|
| 9 |
NCT02365532 |
Completed |
Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults |
|
- Drug: GS-6615
- Drug: Placebo to match GS-6615
- Drug: Placebo to match dofetilide
- Drug: Dofetilide
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in daytime QT interval corrected for heart rate using the Fridericia formula (QTcF)
- Pharmacokinetic (PK) profiles of GS-6615 and dofetilide
- Incidence of adverse events, clinical laboratory test results, vital sign measurements, and electrocardiogram (ECG) data
|
60 |
All |
18 Years to 40 Years (Adult) |
NCT02365532 |
GS-US-372-1666 |
|
February 2015 |
May 2015 |
May 2015 |
February 19, 2015 |
May 20, 2015 |
|
- Spaulding Clinical Research, LLC
West Bend, Wisconsin, United States
|
| 10 |
NCT01745666 |
Recruiting |
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients |
- Long QT Syndrome Type 1 or 2
|
- Other: exercise test
- Other: Epinephrine test
|
Interventional |
Not Applicable |
- Nantes University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- to evaluate the best stress exam (exercise test OR epinephrine test)to unmask long QT syndrome.
- to evaluate each test characteristics
|
130 |
All |
15 Years and older (Child, Adult, Senior) |
NCT01745666 |
RC11_0160 |
QT long |
May 2012 |
May 2018 |
May 2018 |
December 10, 2012 |
October 5, 2016 |
|
- Bordeaux Universitary Hospital
Bordeaux, France - Marseille Universitary Hospital
Marseille, France - CHU Montpellier
Montpellier, France - (and 5 more...)
|
| 11 |
NCT01728025 |
Unknown † |
Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine |
|
|
Interventional |
Phase 2 |
- Tel-Aviv Sourasky Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of participants with syncope and/or documented ventricular arrhythmia
- Change in corrected QT interval
|
10 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01728025 |
TASMC-12-SV-0363-10-CTIL |
|
October 2012 |
November 2017 |
November 2017 |
November 16, 2012 |
March 26, 2015 |
|
- Tel Aviv Medical Center
Tel Aviv, Israel
|
| 12 |
NCT01849003 |
Completed |
Study of the Effect of GS-6615 in Subjects With LQT-3 |
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in QTc intervals (Fridericia formula)
- Incidence of Adverse Events (AEs)
- Changes in ECHO parameters
- (and 5 more...)
|
24 |
All |
18 Years to 65 Years (Adult) |
NCT01849003 |
GS-US-279-0110 |
|
May 2013 |
November 2014 |
November 2014 |
May 8, 2013 |
November 17, 2014 |
|
- University of Rochester Medical Center/Strong Memorial Hospital
Rochester, New York, United States
|
| 13 |
NCT02412098 |
Completed |
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function |
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PK Parameter: AUC_0-inf of eleclazine and its metabolite GS-623134
- PK Parameter: Cmax of eleclazine and its metabolite GS-623134
- Incidence of adverse events
- Proportion of participants with laboratory abnormalities
|
49 |
All |
18 Years to 65 Years (Adult) |
NCT02412098 |
GS-US-372-1048
2014-005266-30 |
|
March 2015 |
April 2016 |
April 2016 |
April 8, 2015 |
April 29, 2016 |
|
- Miami, Florida, United States
- Orlando, Florida, United States
- Minneapolis, Minnesota, United States
- (and 5 more...)
|
| 14 |
NCT01648205 |
Recruiting |
Efficacy Study of Sodium Channel Blocker in LQT3 Patients |
|
- Drug: Placebo
- Drug: Ranolazine
|
Interventional |
Phase 2 |
- University of Rochester
- Gilead Sciences
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- QTc duration
- Change in Novel ECG, Echo, and Holter-derived markers from baseline at 2 and 6 months
|
60 |
All |
21 Years and older (Adult, Senior) |
NCT01648205 |
IN-US-259-0128 |
|
September 2012 |
December 2018 |
December 2018 |
July 24, 2012 |
December 8, 2017 |
|
- University of Rochester
Rochester, New York, United States
|
| 15 |
NCT02439658 |
Recruiting |
Genetics of QT Prolongation With Antiarrhythmics |
- Long QT Syndrome
- Drug Toxicity
|
- Drug: Dofetilide and/or sotalol
|
Observational |
|
- Massachusetts General Hospital
- VA Office of Research and Development
- Beth Israel Deaconess Medical Center
- Brigham and Women's Hospital
|
Other / U.S. Fed |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- QT interval
- Successful drug initiation
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT02439658 |
2013P001851 |
DOFEGEN |
January 2014 |
January 2019 |
January 2019 |
May 12, 2015 |
March 29, 2016 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Brigham and Womens Hospital
Boston, Massachusetts, United States - West Roxbury VA Medical Center
West Roxbury, Massachusetts, United States
|
| 16 |
NCT02082431 |
Recruiting |
Long QT and Hearing Loss Registry |
- Sensorineural Hearing Loss
- Long QT Syndrome
|
|
Observational |
|
- Mednax Center for Research, Education, Quality and Safety
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The incidence of an abnormal ECG (QTc > 450) in neonates greater than a week of age with either unilateral or bilateral sensorineural hearing loss
- In neonates > 1 week of age with either bilateral or unilateral sensorineural hearing loss and an abnormal ECG, percentage have an identifiable genetic mutation
|
600 |
All |
up to 90 Days (Child) |
NCT02082431 |
PDX-001-13 |
|
August 2014 |
December 2018 |
December 2018 |
March 10, 2014 |
February 1, 2018 |
|
- Jack Jacob
Anchorage, Alaska, United States - Banner Good Samaritan Hospital
Phoenix, Arizona, United States - St. Joseph's Hospital & Medical Center
Phoenix, Arizona, United States - (and 11 more...)
|
| 17 |
NCT02775513 |
Active, not recruiting |
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia |
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02775513 |
LQTS |
|
September 2010 |
May 2016 |
|
May 17, 2016 |
May 17, 2016 |
|
|
| 18 |
NCT02441829 |
Completed |
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function |
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasma pharmacokinetics (PK) profiles of eleclazine and its metabolite GS-623134: AUC_0-inf and Cmax
- Safety profile of eleclazine as measured by incidence of adverse events and laboratory abnormalities
|
55 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02441829 |
GS-US-372-1589
2014-005267-32 |
|
May 2015 |
December 2015 |
December 2015 |
May 12, 2015 |
December 22, 2015 |
|
- DeLand, Florida, United States
- Miami, Florida, United States
- Orlando, Florida, United States
- (and 4 more...)
|
| 19 |
NCT02043925 |
Completed |
QT-prolongation in Psychiatric Hospitals |
|
- Drug: drugs linked with QT-prolongation
|
Observational |
|
- Katholieke Universiteit Leuven
- Agentschap voor Innovatie door Wetenschap en Technologie
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- change in QTc-interval (corrected for heart rate)
|
152 |
All |
18 Years and older (Adult, Senior) |
NCT02043925 |
VF/2010/02 |
|
October 2010 |
March 2015 |
March 2015 |
January 23, 2014 |
July 28, 2015 |
|
- Psychiatrisch Centrum Sint-Jan
Eeklo, Belgium
|
| 20 |
NCT02549664 |
Recruiting |
Exercise in Genetic Cardiovascular Conditions |
- Hypertrophic Cardiomyopathy
- Long QT Syndrome
|
|
Observational |
|
- Yale University
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Composite risk of death, cardiac arrest, ventricular arrhythmias, or syncope in individuals with HCM or LQTS who are participating in moderate or vigorous exercise and in sedentary individuals.
- Emotional Quality of Life assessed using Pediatric Cardiac Quality of Life Inventory (Pcqli)
- Physical Quality of Life assessed using Pediatric Quality of Life Inventory (PedsQL)
- Physical Quality of Life assessed using Health Status Questionnaire (SF36) Quality of Life for Adults
|
4286 |
All |
8 Years to 60 Years (Child, Adult) |
NCT02549664 |
1411014982
1R01HL125918-01 |
LIVE-HCM/LQT |
May 2015 |
May 2018 |
May 2020 |
September 15, 2015 |
October 18, 2017 |
|
- University of Arizona
Tucson, Arizona, United States - Cedar Sinai/LA Cardiology
Los Angeles, California, United States - University of California Irvine
Orange, California, United States - (and 36 more...)
|
| 21 |
NCT02043912 |
Completed |
Drug Interactions With Risk of QT-prolongation in a General Hospital |
|
|
Observational |
|
- Katholieke Universiteit Leuven
- Agentschap voor Innovatie door Wetenschap en Technologie
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- QTc-interval (corrected for heart rate)
- number of drug interactions (with risk of QT-prolongation)
|
222 |
All |
18 Years and older (Adult, Senior) |
NCT02043912 |
EV002 |
|
July 2013 |
February 2014 |
April 2014 |
January 23, 2014 |
June 11, 2014 |
|
- Universitair Ziekenhuis Leuven
Leuven, Belgium
|
| 22 |
NCT03291145 |
Enrolling by invitation |
Exploring Mechanisms and Morphology of QT Interval Prolongation |
- Long Qt Syndrome 1-2
- Sudden Cardiac Death
|
- Drug: Beta Blockers
- Drug: Spironolactone
|
Interventional |
Not Applicable |
- Herlev and Gentofte Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
|
50 |
All |
18 Years to 60 Years (Adult) |
NCT03291145 |
260910000001 |
TriQarr |
June 27, 2017 |
June 27, 2018 |
January 1, 2020 |
September 25, 2017 |
September 25, 2017 |
|
- Herlev-Gentofte Hospital
Herlev, Copenhagen, Denmark
|
| 23 |
NCT02814981 |
Recruiting |
Hydroxyzine and Risk of Prolongation of QT Interval |
- Hydroxyzine
- Long QT Syndrome
|
|
Observational |
|
- University Hospital, Caen
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Measure of the corrected QT interval in ms
- Number of Incoming of torsade de pointe
- risk of sudden death by ventricular arythmia
|
130 |
All |
18 Years and older (Adult, Senior) |
NCT02814981 |
A15-D44-VOL.27 |
HYDROXYZINE-QT |
November 2015 |
August 2017 |
October 2017 |
June 28, 2016 |
June 28, 2016 |
|
- Alexandre Joachim
Caen, Basse Normandie, France
|
| 24 |
NCT00005176 |
Completed |
Long QT Syndrome-Population Genetics and Cardiac Studies |
- Cardiovascular Diseases
- Heart Diseases
- Ventricular Arrhythmia
- Long QT Syndrome
|
|
Observational |
|
- University of Rochester
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- None. This is an observational study.
|
2125 |
All |
up to 100 Years (Child, Adult, Senior) |
NCT00005176 |
1053
R01HL033843-16 |
LQTS |
August 1985 |
April 2013 |
April 2013 |
May 26, 2000 |
October 22, 2015 |
|
- University of Rochester
Rochester, New York, United States
|
| 25 |
NCT00588965 |
Completed
Has Results |
Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects |
- Long QT Syndrome
- Cardiac Repolarization
|
- Drug: Placebo
- Drug: Propranolol LA
|
Interventional |
Not Applicable |
- MetroHealth Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- QTc Response to Exercise on Versus Off Beta-blocker.
- Tpeak-end Interval (Tpe)
|
36 |
All |
18 Years to 55 Years (Adult) |
NCT00588965 |
IRB07-00418
NIH grant, GCRC MO1 RR000080 |
|
August 2007 |
December 2008 |
December 2008 |
January 9, 2008 |
July 30, 2013 |
July 30, 2013 |
|
| 26 |
NCT00316459 |
Completed |
Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects |
|
|
Interventional |
Phase 1 |
- Wyeth is now a wholly owned subsidiary of Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To assess the effect of ERB-041 after multiple oral doses on cardiac repolarization as assessed by the QTc interval
- To characterize pharmacokinetic and pharmacodynamic relationships as it relates to QTc.
|
64 |
All |
18 Years to 55 Years (Adult) |
NCT00316459 |
3142A2-110 |
|
May 2006 |
|
|
April 20, 2006 |
April 13, 2007 |
|
- Miami, Florida, United States
|
| 27 |
NCT02068170 |
Completed |
Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital |
|
- Drug: Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib
|
Observational |
|
- Katholieke Universiteit Leuven
- Agentschap voor Innovatie door Wetenschap en Technologie
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- change in QTc-interval (corrected for heart rate)
|
178 |
All |
18 Years and older (Adult, Senior) |
NCT02068170 |
EV003 |
RISQ-PATH |
February 2014 |
March 2015 |
June 2015 |
February 21, 2014 |
July 28, 2015 |
|
|
| 28 |
NCT01903564 |
Completed
Has Results |
Fetal and Neonatal Magnetophysiology |
- Fetal Arrhythmia
- Abnormality in Fetal Heart Rate or Rhythm
- Long QT Syndrome
|
- Device: magnetocardiography
- Device: postnatal ECG
- Device: fetal echocardiography
|
Observational |
|
- University of Wisconsin, Madison
- Shared Medical Technology, Inc.
- Medical College of Wisconsin
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / Industry / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Subjects Experiencing Symptoms
- Percentage of Subjects Experiencing Adverse Events Unrelated to Device
- Number of Participants With Concordance of fMCG and Postnatal ECG for Diagnosis of Long QT Syndrome
- (and 3 more...)
|
39 |
Female |
18 Years to 60 Years (Adult) |
NCT01903564 |
2013-0362
R01HL063174 |
|
March 2014 |
June 2016 |
June 2016 |
July 19, 2013 |
February 7, 2018 |
February 7, 2018 |
- University of Wisconsin-Madison
Madison, Wisconsin, United States
|
| 29 |
NCT00399412 |
Completed |
ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients |
- Long QT Syndrome
- Wide QRS Complexes
- Heart Failure
- Cardiac Resynchronisation
|
|
Observational |
|
- Boston Scientific Corporation
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
86 |
All |
18 Years and older (Adult, Senior) |
NCT00399412 |
DN-05291 |
|
November 2006 |
December 2007 |
December 2007 |
November 14, 2006 |
February 16, 2017 |
|
- Papworth Hospital NHS Trust
Papworth Everard, Cambridge, United Kingdom
|
| 30 |
NCT02380365 |
Unknown † |
QT-Prolongation in Lung Transplantation |
- Disorder Related to Lung Transplantation
|
- Device: Electrocardiography
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- prevalence of significant QTc-interval prolongation (500 msec or above) after lung transplantation
|
720 |
All |
18 Years and older (Adult, Senior) |
NCT02380365 |
2602-2015 |
TX-QTC |
April 2015 |
April 2016 |
July 2016 |
March 5, 2015 |
March 5, 2015 |
|
- Department of Respiratory Medicine, Medizinische Hochschule Hannover
Hannover, Germany
|
| 31 |
NCT00883610 |
Completed |
Effects Rapid Atrial Pacing Has on the Electrocardiogram (ECG) in Patients With Dual Chamber Pacemakers |
|
|
Observational |
|
- Vanderbilt University
- National Institutes of Health (NIH)
- Wake Forest University Health Sciences
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Determine the effect of abrupt changes in atrial rate on QT intervals
|
12 |
All |
21 Years and older (Adult, Senior) |
NCT00883610 |
070070 |
|
April 2009 |
June 2012 |
June 2012 |
April 17, 2009 |
December 11, 2014 |
|
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
|
| 32 |
NCT02439645 |
Recruiting |
A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes |
- Long qt Syndrome
- Torsade de Pointes
|
|
Observational |
|
- Massachusetts General Hospital
- VA Office of Research and Development
- Beth Israel Deaconess Medical Center
- (and 4 more...)
|
Other / U.S. Fed |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Torsade de pointes arrhythmia events
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02439645 |
2008A055317 |
BA-TdP |
October 2013 |
October 2018 |
October 2018 |
May 12, 2015 |
March 29, 2016 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Boston University Medical Center
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - West Roxbury VA Medical Center
West Roxbury, Massachusetts, United States
|
| 33 |
NCT02014961 |
Recruiting |
Worm Study: Modifier Genes in Sudden Cardiac Death |
- Brugada Syndrome
- Long QT Syndrome 3
|
- Procedure: Dermal biopsy
- Behavioral: Gastro-intestinal questionnaire
- Genetic: Whole-exome sequencing
|
Interventional |
Not Applicable |
- Maastricht University Medical Center
- Netherlands Heart Foundation
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Diagnostic
|
- Difference in genetic profile (e.g. modifier genes) between mutation carriers expressing different phenotypes and non-mutation carriers.
|
223 |
All |
18 Years and older (Adult, Senior) |
NCT02014961 |
METC 142060 |
|
April 2015 |
April 2025 |
April 2025 |
December 19, 2013 |
May 14, 2015 |
|
- Maastricht University Medical Center
Maastricht, Limburg, Netherlands
|
| 34 |
NCT02365506 |
Completed |
Effect of Eleclazine on QT, Safety, and Tolerability in Adults With Long QT2 Syndrome |
|
- Drug: Eleclazine
- Drug: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in daytime QT interval corrected for heart rate using the Fridericia formula (QTcF)
- Change in daily QT interval
- Maximal QT shortening
|
13 |
All |
18 Years to 65 Years (Adult) |
NCT02365506 |
GS-US-394-1658
2015-002413-30 |
|
July 2015 |
May 2016 |
June 2016 |
February 19, 2015 |
July 12, 2016 |
|
- University of Rochester Medical Center/Strong Memorial Hospital
Rochester, New York, United States
|
| 35 |
NCT02119091 |
Unknown † |
Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers |
|
|
Interventional |
Phase 1 |
- Haiyan Li
- Food and Drug Administration (FDA)
- Spaulding Clinical Research LLC
- (and 3 more...)
|
Other / U.S. Fed / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
80 |
All |
18 Years to 45 Years (Adult) |
NCT02119091 |
PUTH_CTC_2013_001 |
|
April 2014 |
June 2014 |
December 2014 |
April 21, 2014 |
April 21, 2014 |
|
- Spaulding Clinical Research LLC
West Bend, Wisconsin, United States - Peking University Third Hospital Clinical Trial Center
Beijing, Beijing, China
|
| 36 |
NCT01553734 |
Completed |
Does Azithromycin Cause QT Prolongation in Hospitalized Patients With Severe Community Acquired Pneumonia? |
|
|
Observational |
|
- HaEmek Medical Center, Israel
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Corrected QT segment of ECG
|
148 |
All |
18 Years and older (Adult, Senior) |
NCT01553734 |
EMC-130-11 |
|
March 2012 |
May 2013 |
May 2013 |
March 14, 2012 |
August 31, 2016 |
|
- HaEmek Medical Center
Afula, Israel
|
| 37 |
NCT03158701 |
Not yet recruiting |
Prevelance of Fragmented QRS Complex and Prolonged QT Interval in Cirrhotic Patients |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- the measurement that will be used is the presence of fragmented QRS complex and prolonged QT interval in Electrocardiography in patients with liver cirrhosis
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT03158701 |
assiut university 7000 |
|
June 1, 2017 |
June 1, 2018 |
June 1, 2018 |
May 18, 2017 |
May 18, 2017 |
|
|
| 38 |
NCT00005250 |
Completed |
Linkage Study of Long QT Syndrome In An Amish Kindred |
- Heart Diseases
- Cardiovascular Diseases
- Tachycardia, Ventricular
- (and 2 more...)
|
|
Observational |
|
- National Heart, Lung, and Blood Institute (NHLBI)
|
NIH |
|
|
|
Male |
up to 100 Years (Child, Adult, Senior) |
NCT00005250 |
1132
R01HL041035 |
|
January 1990 |
|
December 1992 |
May 26, 2000 |
May 13, 2016 |
|
|
| 39 |
NCT03070470 |
Completed |
CiPA Phase 1 ECG Biomarker Validation Study |
- Drug-induced QT Prolongation
- Pharmacokinetics
- Pharmacodynamics
|
- Drug: Ranolazine
- Drug: Verapamil
- Drug: Lopinavir / Ritonavir
- (and 3 more...)
|
Interventional |
Phase 1 |
- Food and Drug Administration (FDA)
- Spaulding Clinical Research LLC
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Absence of J-Tpeakc prolongation with "balanced ion channel" drugs (ranolazine, verapamil, lopinavir / ritonavir)
- QTc prolongation with "predominant hERG" blocking drug (chloroquine)
- QTc and J-Tpeakc shortening from calcium block (diltiazem) in the presence of hERG block (dofetilide)
|
57 |
All |
18 Years to 50 Years (Adult) |
NCT03070470 |
16-086D
SCR-004 |
|
March 14, 2017 |
June 26, 2017 |
June 26, 2017 |
March 3, 2017 |
September 1, 2017 |
|
- Spaulding Clinical Research
West Bend, Wisconsin, United States
|
| 40 |
NCT02308748 |
Completed
Has Results |
Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block |
- Drug-induced QT Prolongation
- Pharmacokinetics
- Pharmacodynamics
|
- Drug: Dofetilide
- Drug: Mexiletine
- Drug: Lidocaine
- (and 3 more...)
|
Interventional |
Phase 1 |
- Food and Drug Administration (FDA)
- Spaulding Clinical Research LLC
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in Placebo Corrected Change From Baseline QTc and J-Tpeakc Intervals on the ECG Measured in Milliseconds When Dofetilide is Administered With Mexiletine or Lidocaine Compared to When Dofetilide is Administered Alone at Evening Dose on Treatment Day
- Change in Placebo Corrected Change From Baseline QTc Interval on the ECG Measured in Milliseconds When Moxifloxacin is Administered With Diltiazem at the Evening Dose Compared to When Moxifloxacin is Administered Alone at Afternoon Dose on Treatment Day.
|
22 |
All |
18 Years to 35 Years (Adult) |
NCT02308748 |
14-022D
SCR-003 |
|
May 2014 |
June 2014 |
June 2014 |
December 4, 2014 |
June 8, 2016 |
June 8, 2016 |
|
| 41 |
NCT00221832 |
Unknown † |
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases |
- Long QT Syndrome
- Hypertrophic Cardiomyopathy
- Arrhythmogenic Right Ventricular Dysplasia
|
|
Observational |
|
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
|
300 |
All |
Child, Adult, Senior |
NCT00221832 |
0261.5 |
|
October 2003 |
|
December 2011 |
September 22, 2005 |
January 13, 2010 |
|
- University Hospital Mannheim, I. Department of Medicine
Mannheim, Germany
|
| 42 |
NCT02513940 |
Completed |
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes |
- Prolonged QT Interval in EKG and Sudden Death
|
- Drug: Testosterone
- Drug: Progesterone
- Drug: Placebo
- Drug: Ibutilide
|
Interventional |
Phase 4 |
- Indiana University
- American Heart Association
- Purdue University
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Baseline (pre-ibutilide) individualized rate-corrected QT interval (QTcI)
- Maximum QTcI following ibutilide 0.003 mg/kg
- Maximum % change from pretreatment value in QTcI following ibutilide 0.003 mg/kg
- (and 2 more...)
|
14 |
Male |
65 Years and older (Adult, Senior) |
NCT02513940 |
1507526854 |
|
May 2016 |
October 19, 2017 |
October 19, 2017 |
August 3, 2015 |
April 23, 2018 |
|
- Indiana University
Indianapolis, Indiana, United States
|
| 43 |
NCT01929083 |
Completed
Has Results |
Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening |
- Prolonged QT Interval in EKG and Sudden Death
|
- Drug: Progesterone
- Drug: Placebo
- Drug: Ibutilide
|
Interventional |
Phase 2 |
- Indiana University
- American Heart Association
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Baseline (Pre-Ibutilide) QTcI Intervals
- Maximum Individual-corrected QT Interval (QTcI)
- Maximum % Change From Baseline in QTcI Intervals Following Ibutilide Administration
- (and 2 more...)
|
19 |
Female |
21 Years to 40 Years (Adult) |
NCT01929083 |
12GRNT12060187 |
|
April 2013 |
June 2014 |
June 2014 |
August 27, 2013 |
October 30, 2015 |
September 28, 2015 |
- Indiana Clinical Research Center
Indianapolis, Indiana, United States - Purdue University
Indianapolis, Indiana, United States
|
| 44 |
NCT02413450 |
Enrolling by invitation |
Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias |
- Inherited Cardiac Arrythmias
- Long QT Syndrome (LQTS)
- Brugada Syndrome (BrS)
- (and 7 more...)
|
|
Observational |
|
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- •Production of cardiomyocytes and engineered tissues from hiPSC-derived cardiomyocytes to be used in mechanistic studies of disease and testing of therapeutic interventions.
|
100 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02413450 |
NA_00085175 |
|
August 2013 |
August 2023 |
August 2023 |
April 10, 2015 |
August 14, 2017 |
|
- Johns Hopkins Medical Institute
Baltimore, Maryland, United States
|
| 45 |
NCT03182777 |
Recruiting |
Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies |
- Channelopathies
- Brugada Syndrome
- Long QT Syndrome
- Ventricular, Tachycardia
|
- Procedure: Dental restorative procedure
|
Interventional |
Not Applicable |
- University of Sao Paulo General Hospital
- Fundação de Amparo à Pesquisa do Estado de São Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Sustained ventricular tachycardia
|
30 |
All |
6 Years and older (Child, Adult, Senior) |
NCT03182777 |
Odonto-Canalopatias |
SLDAPCC |
May 2015 |
December 2017 |
April 2019 |
June 9, 2017 |
June 9, 2017 |
|
- Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, Brazil
|
| 46 |
NCT00005367 |
Completed |
Epidemiology of Long QTand Asian Sudden Death in Sleep |
- Cardiovascular Diseases
- Heart Diseases
- Arrhythmia
- (and 2 more...)
|
|
Observational |
|
- National Heart, Lung, and Blood Institute (NHLBI)
|
NIH |
|
|
|
Male |
Child, Adult, Senior |
NCT00005367 |
4254 |
|
February 1993 |
|
January 1995 |
May 26, 2000 |
June 24, 2005 |
|
|
| 47 |
NCT00335036 |
Terminated |
Pediatric Lead Extractability and Survival Evaluation (PLEASE) |
- Ventricular Tachycardia
- Ventricular Fibrillation
- Cardiomyopathy
- (and 2 more...)
|
- Device: ICD lead implant
- Device: Thin leads
|
Interventional |
Not Applicable |
- Charles Berul
- Medtronic
- Guidant Corporation
- Children's Research Institute
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- ICD lead functionality and performance by subtype
- Lead extractability by subtype
- Comparison of implant electrical parameters
- (and 3 more...)
|
55 |
All |
1 Year to 55 Years (Child, Adult) |
NCT00335036 |
CHB-05-11-147 |
|
June 2006 |
January 2009 |
January 2009 |
June 8, 2006 |
July 7, 2017 |
|
- Children's Hospital Boston
Boston, Massachusetts, United States
|
| 48 |
NCT03278522 |
Completed |
Ramosetron Pre-treatment for PONV and QT Prolongation |
- PONV
- Prolonged QTc Interval
|
|
Interventional |
Phase 4 |
- Konkuk University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Prevention
|
|
64 |
Female |
19 Years to 99 Years (Adult, Senior) |
NCT03278522 |
KUH1160112 |
|
July 1, 2017 |
February 28, 2018 |
February 28, 2018 |
September 11, 2017 |
March 9, 2018 |
|
- Lee Sung Ho
Seoul, Korea, Republic of
|
| 49 |
NCT00292032 |
Recruiting |
Registry of Unexplained Cardiac Arrest |
- Cardiac Arrest
- Long QT Syndrome
- Brugada Syndrome
- (and 4 more...)
|
|
Observational |
|
- University of British Columbia
- Heart and Stroke Foundation of Ontario
- Boston Scientific Corporation
- Medtronic
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Developing and Testing Algorithms for Diagnostics and Treatments in Survivors of Unexplained Cardiac Arrest
|
1500 |
All |
2 Years and older (Child, Adult, Senior) |
NCT00292032 |
R-04-099
10076 |
|
May 2004 |
January 2019 |
January 2020 |
February 15, 2006 |
May 17, 2016 |
|
- University of British Columbia
Vancovuer, British Columbia, Canada
|
| 50 |
NCT01338441 |
Completed |
Selections of Subjects With Important Changes in Their Cardiac Repolarization Parameters for the Procurement of Skin and Blood Samples |
|
- Drug: Erythromycin
- Drug: Placebo
|
Interventional |
Phase 1 |
- Ectycell SASU
- Pierre and Marie Curie University
- Institut National de la Santé Et de la Recherche Médicale, France
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
|
- Prolongation of cardiac QT due to erythromycin compare to Placebo reported as Delta QTcf
- Comparison Delta QTcf eryhtromycin-sotalol
- Assess the effect of erythromycin Twave morphologie changes
|
130 |
All |
18 Years to 40 Years (Adult) |
NCT01338441 |
2010-022000-41 |
iQTEST |
March 2011 |
May 2011 |
August 2011 |
April 19, 2011 |
September 15, 2011 |
|
- BIOTRIAL
Rueil Malmaison, France
|
Create an RSS feed from your search for:
Download the search results for: